David Michael C, Higashi Hideki
School of Medicine and Dentistry, Griffith University, Gold Coast, Australia.
The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, New South Wales, Australia.
J Health Econ Outcomes Res. 2024 Apr 11;11(1):103-111. doi: 10.36469/001c.94460. eCollection 2024.
Unilateral cerebral palsy is a major cause of childhood disability and a substantial economic burden. Intensive group-based therapy, consisting of hybrid constraint-induced movement and bimanual therapies, has been shown to be effective in improving specific quality-of-life domains in children with this disability. Our objective in this study was to assess if this intervention was cost-effective compared with standard care. An open-label, parallel, randomized controlled trial with an embedded economic evaluation of the intervention was conducted. A total of 47 children were randomized to either the intervention group (n = 27) or the standard care (n = 20) group. The effectiveness of the intervention was assessed using the Cerebral Palsy Quality of Life (Child) questionnaire across several domains. Nonparametric bootstrapping was used to quantify uncertainty intervals (UIs) for incremental cost-effectiveness ratios. The incremental cost-effectiveness ratios for the intervention were 107 to 1071 (95% UI: -4606) for Family Health and 6448 to 1000, only for the Pain and Impact of Disability domain was the intervention likely to have a probability of being cost-effective exceeding 0.75. Other than the Pain and Impact of Disability domain, there was insufficient evidence demonstrating the intervention to be cost-effective over a 13-week time horizon.
单侧脑瘫是儿童残疾的主要原因,也是一项沉重的经济负担。由混合性强制性运动疗法和双手疗法组成的强化小组治疗,已被证明能有效改善患有这种残疾的儿童特定的生活质量领域。我们这项研究的目的是评估这种干预措施与标准护理相比是否具有成本效益。我们进行了一项开放标签、平行、随机对照试验,并对干预措施进行了嵌入式经济评估。共有47名儿童被随机分为干预组(n = 27)或标准护理组(n = 20)。使用脑瘫儿童生活质量问卷在多个领域评估干预措施的有效性。采用非参数自举法来量化增量成本效益比的不确定性区间(UI)。干预措施在家庭健康方面的增量成本效益比为107至1071(95% UI:-4606),在疼痛和残疾影响方面为6448至1000,只有在疼痛和残疾影响领域,干预措施具有成本效益的概率才可能超过0.75。除了疼痛和残疾影响领域外,没有足够的证据表明在13周的时间范围内该干预措施具有成本效益。